Class Year: G3
Hometown: Cambridge, Ontario, Canada
Undergraduate Education: BS/08 Chemistry & Physiology/U of W. Ontario
Research Interest: drug discovery, leukemia and lymphoma and other blood disorders, sphingolipid signaling
Advisor: Thomas Loughran, MD
Graduate Program: Molecular Medicine
Description: LGL leukemia is a rare proliferative disorder with two classifications - CD3+T-LGL and CD3-/NK-LGL. These patients typically present with various cytopenias leading to complications such as anemia and chronic infection associated with neutropenia. In addition, there is an unusual association with a variety of autoimmune diseases. My project focuses on the NK-LGL subtype and will investigate the sphingolipid rheostat and it's role in leukemia pathogenesis; specifically sphingosine-1-phosphat signaling through S1PR5 and it's role as a survival pathway. This will hopefully uncover possible therapeutic targets as NK-LGL is currently an incurable disease, with death occurring in the acute form within a few months of diagnosis.
American Society of Hematology (ASH), Atlanta, GA
Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, Stiles B, Rountree CB (2010) Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion Hepatology 52(3):945-53
LeBlanc F, Zhang D, Liu X, Loughran Jr. TP (2012) LGL leukemia: From dysregulated pathways to therapeutic targets Future Oncology 8(7):1-15
| || |
Media interested in contacting the above person should contact the Office of Marketing and Communications at 717-531-8606.